Is Becton, Dickinson & Co. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Becton, Dickinson & Co. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 2.52, and an EV to EBITDA of 16.57. In comparison to peers, Abbott Laboratories has a fair P/E of 18.36, while Stryker Corp. also shows an expensive valuation with a P/E of 33.17.
The recent stock performance further highlights this valuation concern, as Becton, Dickinson & Co. has underperformed against the S&P 500 with a year-to-date return of -16.65% compared to the index's 13.30%. This trend continues over longer periods, with a 5-year return of -18.16% versus the S&P 500's 91.29%, reinforcing the notion that the stock may be overvalued relative to its peers and market performance.